Myriad Genetics Inc (MYGN)vsWaters Corporation (WAT)
MYGN
Myriad Genetics Inc
$6.04
+3.25%
HEALTHCARE · Cap: $556.68M
WAT
Waters Corporation
$459.90
+2.31%
HEALTHCARE · Cap: $47.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 476% more annual revenue ($4.64B vs $806.60M). WAT leads profitability with a 3.6% profit margin vs -14.0%. MYGN appears more attractively valued with a PEG of 1.40. MYGN earns a higher WallStSmart Score of 44/100 (D).
MYGN
Hold44
out of 100
Grade: D
WAT
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MYGN.
Margin of Safety
-44.6%
Fair Value
$227.71
Current Price
$459.90
$232.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -37.0% — below average capital efficiency
Revenue declined 10.5%
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 121.5x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
MYGN profiles as a turnaround stock while WAT is a hypergrowth play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
WAT is growing revenue faster at 113.4% — sustainability is the question.
WAT generates stronger free cash flow (153M), providing more financial flexibility.
Bottom Line
MYGN scores higher overall (44/100 vs 43/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?